Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
BUSINESS
Nippon BI Logs 4% Growth on NHI Price-Based Sales; Jardiance, Ofev as Engines
Nippon Boehringer Ingelheim saw its pharma sales in 2022 grow 4% over the prior year on an NHI price basis as it continued to enjoy rosy revenue streams from the SGLT2 inhibitor Jardiance (empagliflozin) and Ofev (nintedanib), a drug for…
To read the full story
Related Article
- Boehringer’s Japan Pharma Sales Up for 7th Straight Year, 10-Plus Launches Eyed by 2030
June 4, 2026
- Boehringer’s Japan Pharma Sales Up 7% in 2023, Buoyed by Ofev, Jardiance
May 29, 2024
- Boehringer’s Japan Human Pharma Sales Up 5.6% in 2022
March 30, 2023
- Shashank Deshpande to Take Reins at Nippon Boehringer Ingelheim
June 2, 2022
BUSINESS
- Astellas on Track to Hit 30% Margin Goal Early after Strong H1 Scorecards
November 5, 2026
- Nxera Inks US$1.47 Billion Deal with AbbVie for IBD Drug
November 5, 2026
- Kissei Might Revise Midterm Targets as Tavneos Faces Approval Revocation
November 5, 2026
- Boehringer, Lung Cancer Society Launch 5-Year Hernexeos Real-World Study
November 5, 2026
- ASKA Snags Japan Rights to Minghui’s TED Therapy
November 5, 2026
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…